{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:39:48Z","timestamp":1780922388537,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Roche Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00277-021-04548-2","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T04:08:38Z","timestamp":1620706118000},"page":"2043-2050","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-275X","authenticated-orcid":false,"given":"Heiner","family":"Zimmermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Nitsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Babel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ritgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pietschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf U.","family":"Trappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the German PTLD Study Group and German Lymphoma Alliance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"4548_CR1","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/ajt.12211","volume":"13","author":"AM Evens","year":"2013","unstructured":"Evens AM, Choquet S, Kroll-Desrosiers AR et al (2013) Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant 13:1512\u20131522. https:\/\/doi.org\/10.1111\/ajt.12211","journal-title":"Am J Transplant"},{"key":"4548_CR2","doi-asserted-by":"publisher","first-page":"33849","DOI":"10.18632\/oncotarget.5292","volume":"6","author":"GM Crane","year":"2015","unstructured":"Crane GM, Powell H, Kostadinov R et al (2015) Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget 6:33849\u201333866. https:\/\/doi.org\/10.18632\/oncotarget.5292","journal-title":"Oncotarget"},{"key":"4548_CR3","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1158\/1078-0432.CCR-17-2685","volume":"24","author":"JP Dugan","year":"2018","unstructured":"Dugan JP, Haverkos BM, Villagomez L et al (2018) Complete and durable responses in primary central nervous system posttransplant lymphoproliferative disorder with zidovudine, ganciclovir, rituximab, and dexamethasone. Clin Cancer Res 24:3273\u20133281. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2685","journal-title":"Clin Cancer Res"},{"key":"4548_CR4","doi-asserted-by":"publisher","first-page":"15088","DOI":"10.1038\/nrdp.2015.88","volume":"2","author":"VR Dharnidharka","year":"2016","unstructured":"Dharnidharka VR, Webster AC, Martinez OM et al (2016) Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers 2:15088. https:\/\/doi.org\/10.1038\/nrdp.2015.88","journal-title":"Nat Rev Dis Primers"},{"key":"4548_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","volume":"13","author":"R Trappe","year":"2012","unstructured":"Trappe R, Oertel S, Leblond V et al (2012) Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 13:196\u2013206. https:\/\/doi.org\/10.1016\/S1470-2045(11)70300-X","journal-title":"Lancet Oncol"},{"key":"4548_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","volume":"35","author":"RU Trappe","year":"2017","unstructured":"Trappe RU, Dierickx D, Zimmermann H et al (2017) Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol 35:536\u2013543. https:\/\/doi.org\/10.1200\/JCO.2016.69.3564","journal-title":"J Clin Oncol"},{"key":"4548_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/cncr.24834","volume":"116","author":"R Cavaliere","year":"2010","unstructured":"Cavaliere R, Petroni G, Lopes MB et al (2010) Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 116:863\u2013870. https:\/\/doi.org\/10.1002\/cncr.24834","journal-title":"Cancer"},{"key":"4548_CR8","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1111\/ajt.12858","volume":"14","author":"SEK Fink","year":"2014","unstructured":"Fink SEK, Gandhi MK, Nourse JP et al (2014) A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors. Am J Transplant 14:2577\u20132587. https:\/\/doi.org\/10.1111\/ajt.12858","journal-title":"Am J Transplant"},{"key":"4548_CR9","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJM Ferreri","year":"2016","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E et al (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217-227. https:\/\/doi.org\/10.1016\/S2352-3026(16)00036-3","journal-title":"Lancet Haematol"},{"key":"4548_CR10","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E et al (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol 4:e510\u2013e523. https:\/\/doi.org\/10.1016\/S2352-3026(17)30174-6","journal-title":"Lancet Haematol"},{"key":"4548_CR11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/bjh.15661","volume":"184","author":"CP Fox","year":"2019","unstructured":"Fox CP, Phillips EH, Smith J et al (2019) Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br J Haematol 184:348\u2013363. https:\/\/doi.org\/10.1111\/bjh.15661","journal-title":"Br J Haematol"},{"key":"4548_CR12","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","volume":"16","author":"K Hoang-Xuan","year":"2015","unstructured":"Hoang-Xuan K, Bessell E, Bromberg J et al (2015) Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 16:e322-332. https:\/\/doi.org\/10.1016\/S1470-2045(15)00076-5","journal-title":"Lancet Oncol"},{"key":"4548_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1182\/asheducation-2013.1.95","volume":"2013","author":"H Zimmermann","year":"2013","unstructured":"Zimmermann H, Trappe RU (2013) EBV and posttransplantation lymphoproliferative disease: what to do? Hematology Am Soc Hematol Educ Program 2013:95\u2013102. https:\/\/doi.org\/10.1182\/asheducation-2013.1.95","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"4548_CR14","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872","volume":"126","author":"D Dierickx","year":"2015","unstructured":"Dierickx D, Tousseyn T, Gheysens O (2015) How I treat posttransplant lymphoproliferative disorders. Blood 126:2274\u20132283. https:\/\/doi.org\/10.1182\/blood-2015-05-615872","journal-title":"Blood"},{"key":"4548_CR15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s11255-012-0146-8","volume":"45","author":"SH Valavoor","year":"2013","unstructured":"Valavoor SH, Ashraf Z, Narwal R, Ratnam S (2013) Conservative management of post-transplant central nervous system lymphoma. Int Urol Nephrol 45:1219\u20131222. https:\/\/doi.org\/10.1007\/s11255-012-0146-8","journal-title":"Int Urol Nephrol"},{"key":"4548_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s11060-010-0425-0","volume":"103","author":"A Patrick","year":"2011","unstructured":"Patrick A, Wee A, Hedderman A et al (2011) High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder. J Neurooncol 103:739\u2013743. https:\/\/doi.org\/10.1007\/s11060-010-0425-0","journal-title":"J Neurooncol"},{"key":"4548_CR17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.18632\/oncotarget.26522","volume":"10","author":"AJJ Velvet","year":"2019","unstructured":"Velvet AJJ, Bhutani S, Papachristos S et al (2019) A single-center experience of post-transplant lymphomas involving the central nervous system with a review of current literature. Oncotarget 10:437\u2013448. https:\/\/doi.org\/10.18632\/oncotarget.26522","journal-title":"Oncotarget"},{"key":"4548_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/pbc.23134","volume":"58","author":"DK Bonney","year":"2012","unstructured":"Bonney DK, Htwe EE, Turner A et al (2012) Sustained response to intrathecal rituximab in EBV associated post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. Pediatr Blood Cancer 58:459\u2013461. https:\/\/doi.org\/10.1002\/pbc.23134","journal-title":"Pediatr Blood Cancer"},{"key":"4548_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/10428194.2012.718342","volume":"54","author":"K Czyzewski","year":"2013","unstructured":"Czyzewski K, Styczynski J, Krenska A et al (2013) Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder. Leuk Lymphoma 54:503\u2013506. https:\/\/doi.org\/10.3109\/10428194.2012.718342","journal-title":"Leuk Lymphoma"},{"key":"4548_CR20","first-page":"453","volume-title":"WHO classification of tumours of haematopoetic and lymphoid tissues, Revised","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow SH, Webber SA, Chadburn A, Ferry JA (2017) Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoetic and lymphoid tissues, Revised, 4th edn. International Agency for Research on Cancer, Lyon, pp 453\u2013462","edition":"4"},{"key":"4548_CR21","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1097\/00007890-199911270-00015","volume":"68","author":"CV Paya","year":"1999","unstructured":"Paya CV, Fung JJ, Nalesnik MA et al (1999) Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS\/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68:1517\u20131525","journal-title":"Transplantation"},{"key":"4548_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2141.2010.08160.x","volume":"149","author":"A Parker","year":"2010","unstructured":"Parker A, Bowles K, Bradley JA et al (2010) Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS Guidelines. Br J Haematol 149:693\u2013705. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08160.x","journal-title":"Br J Haematol"},{"key":"4548_CR23","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJM et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034\u20135043. https:\/\/doi.org\/10.1200\/JCO.2005.13.524","journal-title":"J Clin Oncol"},{"key":"4548_CR24","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1111\/j.1600-6143.2012.04192.x","volume":"12","author":"M Fern\u00e1ndez-Ruiz","year":"2012","unstructured":"Fern\u00e1ndez-Ruiz M, L\u00f3pez-Medrano F, Varela-Pe\u00f1a P et al (2012) Monitoring of immunoglobulin levels identifies kidney transplant recipients at high risk of infection. Am J Transplant 12:2763\u20132773. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04192.x","journal-title":"Am J Transplant"},{"key":"4548_CR25","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","volume":"24","author":"IT Gavrilovic","year":"2006","unstructured":"Gavrilovic IT, Hormigo A, Yahalom J et al (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570\u20134574. https:\/\/doi.org\/10.1200\/JCO.2006.06.6910","journal-title":"J Clin Oncol"},{"key":"4548_CR26","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s00432-017-2423-5","volume":"143","author":"U Herrlinger","year":"2017","unstructured":"Herrlinger U, Sch\u00e4fer N, Fimmers R et al (2017) Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. J Cancer Res Clin Oncol 143:1815\u20131821. https:\/\/doi.org\/10.1007\/s00432-017-2423-5","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04548-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04548-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04548-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T05:09:54Z","timestamp":1626412194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04548-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4548"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04548-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"assertion":[{"value":"5 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The German PTLD registry was approved by the appropriate Ethics committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients provided informed consent to the German PTLD registry according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Dr. Zimmermann reports institutional grants from Atara and Roche, and travel support from Atara, Celgene, and Jansen, outside the submitted work. Dr. Hauser reports personal fees or travel support from Astellas, Biotest, Hexal, Neovii, Novartis, and Roche, all outside the submitted work. Dr. Ritgen reports personal fees from Hoffman LaRoche, AbbVie, AstraZeneca, and Jansen, all outside the submitted work. Claudia Pietschmann reports travel support by KS Pharma, outside the submitted work. Dr. Trappe reports institutional grants from Atara and Roche and non-financial support from Roche, Atara, Celgene, Janssen, and AbbVie, all outside the submitted work. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}